Abstract
Alpha-1 antitrypsin (AAT) is the most abundant proteinase inhibitor within the circulation and AAT deficiency is a genetic disorder characterised by serum levels of less than 11μmol/L. The Z mutation is the most common AAT allele associated with the disease and causes the most severe plasma deficiency, as the mutant protein polymerizes and accumulates within the endoplasmic reticulum of hepatocytes. The retained polymers are associated with cirrhosis and reduced serum levels of AAT contribute to the development of chronic pulmonary disease in AAT deficient individuals. This article will review the importance of AAT as a serine anti-protease, the clinical manifestations of AAT deficiency and specific treatment of the disease. Current therapies including AAT replacement and treatment with synthetic or alternative protease inhibitors are reviewed, along with possible future therapies including those focusing on targeting AAT polymer formation or based on gene therapy.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency
Volume: 9 Issue: 4
Author(s): Emer P. Reeves, Sonya Cosgrove, David A. Bergin, Catherine M. Greene and Noel G. McElvaney
Affiliation:
Abstract: Alpha-1 antitrypsin (AAT) is the most abundant proteinase inhibitor within the circulation and AAT deficiency is a genetic disorder characterised by serum levels of less than 11μmol/L. The Z mutation is the most common AAT allele associated with the disease and causes the most severe plasma deficiency, as the mutant protein polymerizes and accumulates within the endoplasmic reticulum of hepatocytes. The retained polymers are associated with cirrhosis and reduced serum levels of AAT contribute to the development of chronic pulmonary disease in AAT deficient individuals. This article will review the importance of AAT as a serine anti-protease, the clinical manifestations of AAT deficiency and specific treatment of the disease. Current therapies including AAT replacement and treatment with synthetic or alternative protease inhibitors are reviewed, along with possible future therapies including those focusing on targeting AAT polymer formation or based on gene therapy.
Export Options
About this article
Cite this article as:
P. Reeves Emer, Cosgrove Sonya, A. Bergin David, M. Greene Catherine and G. McElvaney Noel, New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (4) . https://dx.doi.org/10.2174/1871523011009040314
DOI https://dx.doi.org/10.2174/1871523011009040314 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cyclooxygenases Regulation by Estradiol on Endothelium
Current Pharmaceutical Design Skin Prick Test with Self-Saliva in Patients with Oral Aphthoses: A New Diagnostic Pathergy for Behcets Disease and Recurrent Aphthosis
Inflammation & Allergy - Drug Targets (Discontinued) New Treatment Options Using 5-HT3 Receptor Antagonists in Rheumatic Diseases
Current Topics in Medicinal Chemistry The role of interleukin 35 in atherosclerosis
Current Pharmaceutical Design Local Treatment for Lymphoid Malignancies of the Eye
Anti-Cancer Agents in Medicinal Chemistry New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Pentoxifylline Use in Dermatology
Inflammation & Allergy - Drug Targets (Discontinued) Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Pharmacogenomics: A Tool to Prevent and Cure Coronary Heart Disease
Current Pharmaceutical Design The Paradoxical Reaction to Rituximab in Six Granulomatosis with Polyangiitis Patients: How Could it be Explained and Managed?
Current Rheumatology Reviews Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Management of Vasculopathy in Connective Tissue Disease
Current Rheumatology Reviews Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Complement System in SLE as a Target for Antibodies
Current Rheumatology Reviews Cell Immunity in Inflammatory Vasculitis
Current Immunology Reviews (Discontinued) Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews